GENEVA--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (“GTC”, Nasdaq: GTCB) and LEO Pharma A/S announced today that ATryn®, the first recombinant human antithrombin therapeutic and the first transgenically produced drug, is being introduced to the international medical community at the International Society on Thrombosis and Haemostasis, or ISTH, Bi-Annual Meeting. ATryn® is being commercialized and further developed in Europe by LEO, GTC’s development and commercialization partner in Europe, Canada and the Middle East.
